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During HIV-1 replication, the viral RNA genome is reverse 
transcribed into a  double stranded DNA by the virally encoded 
multifunctional enzyme reverse transcriptase (RT).1 HIV-1 RT 
remains a major target for continued development of antagonists 
to inhibit virus replication and stem the devastating consequences 
of AIDS.  
Two classes of drugs belonging either to the 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) or 
to the non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
have been used in the clinic as part of the antiretroviral therapy 
against HIV/AIDS.2 NRTIs compete with the natural 
deoxynucleoside triphosphates (dNTPs) during DNA synthesis 
and act as chain terminators.3 In contrast, NNRTIs are non-
competitive inhibitors that bind at an allosteric nonsubstrate 
binding site, which is distinct from the substrate binding site of 
HIV-1 RT.4 While the unique pharmacology of these inhibitors 
has rendered their use in highly active antiretroviral therapy 
(HAART) therapy, HIV-1 has the ability to develop drug 
resistance mutations for both NRTI and NNRTIs.5 Thus, design 
of novel lead compounds that can inhibit wild-type and drug 
resistant HIV-1 RTs is a subject of major interest in anti-HIV 
research. 
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The structural similarity of modified nucleotides to natural 
ribo- and deoxyribonucleoside triphosphates makes them useful 
reagents as substrates or inhibitors for DNA or RNA 
polymerases.6,7 A number of approaches have focused on 
modifications and/or substitutions on the base,8,9 carbohydrate10-15 
and linear triphosphate moieties16-21 to design modified 
nucleotides for diverse applications in nucleic acid and antiviral 
research.  
 
Fig. 1. Chemical structures of β-triphosphotriester 
pronucleotides (1a-c). 
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Dinucleoside phosphorochloridite were synthesized from phosphorus trichloride and three 
nucleoside analogues, 3′-fluoro-2′,3′-dideoxythymidine (FLT), 2',3'-dideoxy-5-fluoro-3'-
thiacytidine (FTC), and 2',3'-dideoxy-3'-thiacytidine (3TC), in a multistep synthesis.  Polymer-
bound N-Boc p-acetoxybenzyl 5′-O-2′-deoxythymidine was reacted with dinucleoside 
phosphorochloridite in the presence of 2,6-lutidine, followed by the reaction with dodecyl 
alcohol and 5-(ethylthio)-1H-tetrazole, oxidation with tert-butyl hydroperoxide, and acidic 
cleavage, respectively, to afford the β-triphosphotriester derivatives containing three different 
nucleosides. 
2009 Elsevier Ltd. All rights reserved.
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Negatively-charged nucleotides have limited cell-
permeability. Masking the phosphate residues with a lipophilic 
chain could generate pronucleotides with improved cellular 
permeability. Prodrugs are chemically modified analogous of the 
active metabolite that can improve pharmacokinetics and 
pharmacodynamics (PK/PD) properties of the active drug. 
However, intracellular chemical transformation needs to be 
occurred in the presence of different enzymes to convert prodrugs 
to their corresponding pharmacologically potent compounds in in 
vivo systems. Prodrug approach offers several advantageous, 
such as enhancing water solubility, improved chemical stability, 
decreased toxicity, and insufficient brain penetration.22 Herein we 
hypothesized that lipophilic pronucleotides can act as prodrugs of 
nucleotide analogs. 
We have previously reported the synthesis of nucleoside 5′-O-
α,β-methylene-β-triphosphates and 5′-O-β,γ-
methylenetriphosphates and their potency towards the enzymatic 
function of wild-type HIV-1 RT.23,24 In continuation of our 
efforts to design a diverse array of modified nucleoside 
triphosphates as RT inhibitors, we report here the synthesis of β-
triphosphotriester pronucleotides (1a−c) of NRTIs, including 3'-
fluoro-3'-deoxythymidine (Alovudine, FLT), 2',3'-dideoxy-3'-
thiacytidine (Lamivudine, 3TC), and 2',3'-dideoxy-5-fluoro-3'-
thiacytidine (Emtricitabine, FTC) (Fig. 1). To the best of our 
knowledge, this is the first report of the synthesis of β-
triphosphotriester pronucleotides containing two RT inhibitors. 
Scheme 1 illustrates the synthesis of nucleoside β-
triphosphitylating reagents containing NRTIs (6a-c). Phosphorus 
trichloride (PCl3, 2 mmol) was reacted with the nucleosides e.g. 
FLT, 3TC, or FTC (2 mmol) in the presence of 2,6-lutidine (2 
mmol) to yield intermediate 5'-O-nucleoside phosphorus 
dichloride (2a-c). In situ reaction of 2a-c with N,N-
diisopropylamine (2 mmol) in the presence of 2,6-lutidine (2 
mmol) afforded intermediate 5'-O-nucleoside N,N-
diisopropylphosphoramidochloridite (3a-c). Addition of water (2 
mmol) and 2,6-lutidine (2 mmol) gave 5'-O-nucleoside N,N-
diisopropyl hydroxyphosphoramide (4a-c) that were reacted with 
phosphorus trichloride (2 mmol) in situ in the presence of 2,6-
lutidine (2 mmol) to afford intermediate compounds 5a-c. The 
intermediates were used immediately for the next reaction under 
extremely dry conditions and nitrogen. 
The reaction of equimolar amounts of 4a-c and 5a-c produced 
5'-O-5'-O-dinucleoside phosphorochloridite (ROH = FLT, R′-OH 
= 3TC (6a); ROH = FLT, R′-OH = FTC (6b); and ROH = FTC, 
R′-OH = 3TC (6c). The chemical structures of 6a-c were 
confirmed by high-resolution time-of-flight electrospray mass 
spectrometry of hydroxyl form of the compounds as shown in the 
Supporting Information. 
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Scheme 1. Preparation of nucleoside β-triphosphitylating 
reagents containing NRTIs 6a-c. 
To accomplish the synthesis of dendritic β-triphosphotriester 
pronucleotides, a diffrentially protected 3′-O-TBDMS-2′-
deoxythymidine (8) was synthesized according to the previously 
reported procedures25-27 (Scheme 2). In this regard, the 5′- and 3′-
hydroxyl groups of 2′-deoxythymidine were protected by tert-
butyldimethylsilyl (TBDMS) by the reaction of the unprotected 
nucleoside with tert-butyldimethylsilyl chloride in the presence 
of imidazole in DMF.25,26 The selective removal of 5′-O-TBDMS 
group in the presence of AcOH/H2O/THF27 afforded 3′-O-
TBDMS-2′-deoxythymidine (8). 
 
Scheme 2. Preparation of 3′-O-TBDMS-2′-deoxythymidine 8. 
Our research on the solid-phase synthesis of 
organophosphorus and organosulfur compounds revealed that the 
polymer-bound N-Boc p-acetoxybenzyl alcohol (9) is a versatile 
solid-phase linker system for the phosphorylation of organic 
compounds27. In this regard the polymer-bound N-Boc p-
acetoxybenzyl alcohol (9) was prepared according to our 
previously reported procedure28 and was used as a loading system 
in this study. Then the polymer-bound N-Boc p-acetoxybenzyl 
trichloracetimidate (10) was prepared from the reaction of (9) 
with trichloroacetonitrile in the presence of DBU according to 
previously reported procedure.28 
Scheme 3 illustrates the synthesis of dendritic nucleoside β-
triphosphate analogs (1a−c). The 2'-deoxy TBDMS protected 2′-
deoxythymidine (8, 3 mmol) was attached to 10 (1.5 mmol) 
through 5′-hydroxyl group in the presence of BF3.OEt2 as acidic 
catalyst29 to afford 11. The deprotection of 3′-O-TBDMS group 
in 11 with tetrabutylammonium fluoride (TBAF) in THF 
afforded (12, ~1.50 mmol), which was divided to three portions 
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(~0.50 mmol each). Each portion of 12 underwent β-
triphosphitylation of 3′-hydroxyl group with β-triphosphitylating 
reagents (6a-c, ~2 mmol, 4 equiv. of 2'-deoxy functions) under 
extremely dry conditions and nitrogen to afford (13a-c). In this 
regard, the prepared reaction mixture containing 6a-c in THF (~2 
mmol) was added to a swelled solution of polymer-bound N-Boc 
p-acetoxybenzyl 5′-O-2′-deoxythymidine 12 (~0.50 mmol) and 
2,6-lutidine (2 mmol) in anhydrous THF. The mixture was 
shaken for 28 h with increasing of temperature from -20 °C to 
room temperature. The resin was collected by filtration, washed 
with THF and MeOH, respectively, and was dried overnight 
under vacuum to give 13a-c.  
1-Dodecanol was used to mask the negatively-charged cell-
impermeable phosphate residues and to improve the lipophilicity 
of the pronucleotides. Thus, 1-dodecanol (4.0 mmol) and 5-
(ethylthio)-1H-tetrazole (4.0 mmol) were added to 13a-c in 
anhydrous THF. The mixtures were shaken for 24 h at room 
temperature, then the resins were collected by filtration, washed 
with DCM and MeOH, respectively, and dried under vacuum to 
give 14a-c. tert-Butyl hydroperoxide in decane was used for the 
oxidation of 14a-c to 15a-c. Finally, the cleavage of polymer-
bound compounds was carried out under acidic conditions 
(DCM/TFA/H2O/1,2-ethanedithiol). The linker-trapped resin 10 
was separated from the final products by filtration. After 
filtration, the solvents were removed using lyophilization and the 
crude products were purified (>98%) using HPLC system to 
afford pure 1a-c products in 51-53% overall yield calculated 
from 10. The chemical structures of the final products (1a−c) 
were determined by nuclear magnetic resonance spectra (1H 
NMR, 13C NMR, and 31P NMR), SELDI-TOF mass spectrometer, 
and quantitative phosphorus analysis. 
Scheme 3. Preparation of pronucleotide derivatives of 3′-fluoro-3′-deoxythymidine, 2',3'-dideoxy-5-fluoro-3'-thiacytidine, and 2',3'-
dideoxy-3'-thiacytidine 1a-c. 
In conclusion, a polymer-bound N-Boc p-acetoxybenzyl 5′-O-
2′-deoxythymidine was reacted with three dinucleoside 
phosphorochloridites containing FLT, FTC, and 3TC in the 
presence of 2,6-lutidine in a solid phase reaction. Subsequent 
conjugation with dodecyl alcohol to mask the negatively charged 
phosphate in the presence of 5-(ethylthio)-1H-tetrazole, oxidation 
with tert-butyl hydroperoxide, and acidic cleavage, respectively, 
afforded the β-triphosphotriester nucleotide derivatives 1a-c 
containing three different nucleosides and a dodecyl chain. The 
compounds will be further evaluated for anti-HIV activities. 
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